Page 15 - Warner Lambert News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Presentation Manor retirement home endures pandemic with strong community April 9, 2021 The day Presentation Manor went into lockdown for COVID-19 was Charles Hendrick’s birthday, but he wasn’t there to celebrate. He had died the previous October of pancreatic cancer. Just before he died, Charles and his wife Anne had moved into Presentation Manor — a Scarborough retirement home founded by almost two dozen religious orders whose older members are the founding residents, living together in a community of communities with lay people such as the Hendricks. Charles got his cancer diagnos...

Over the next few years, some of the best-known biologic medicines will lose patent protection, paving the way for biosimilar medicines to enter the UK market. This article discusses some innovative IP strategies which may be available in the United Kingdom to successfully compete and overcome barriers to market entry. Biologic and biosimilar medicines 'Biosimilars' are medicines that seek to compete with, and are similar to, originator biologic products. Biologics contain active substances that are derived from biological sources and are often large, complex molecules such as antibodies. Bio...

Press release content from PR Newswire. The AP news staff was not involved in its creation. TreeHouse Foods Announces Agreement with JANA Partners March 2, 2021 GMT OAK BROOK, Ill., March 2, 2021 /PRNewswire/ -- TreeHouse Foods, Inc. (NYSE: THS) today announced an agreement with JANA Partners LLC, which owns approximately 7.4% of the outstanding shares of TreeHouse’s common stock, pursuant to which TreeHouse will appoint to its Board of Directors, effective March 2, 2021, two new independent directors: John P. Gainor Jr. and Kenneth I. Tuchman. “We are pleased that our productive engageme...

CoIMMUNE: CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company's board of directors. Dr. Baracchini brings a wealth of biotechnology industry and financial expertise, as well as significant prior board level experience, to the CoImmune board of directors. Dr. Baracchini has over 25 year...

24 feb 2021 CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company’s board of directors. Dr. Baracchini brings a wealth of biotechnology industry and financial expertise, as well as significant prior board level experience, to the CoImmune board of directors. Dr. Baracchini has over 25 ...